IMATINIB DISCONTINUATION AND TKI SWITCHING PATTERNS IN THE RETROSPECTIVE AND PROSPECTIVE COHORTS IN SIMPLICITY, A STUDY OF CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS (PTS) IN ROUTINE CLINICAL PRACTICE

Author(s)

Zyczynski T¹, Khoury J², Goldberg S³, Mauro M⁴, Michallet M⁵, Paquette R⁶, Foreman A⁷, Subar M¹, Turner M⁷, Manley Daumont M⁸, Hehlmann R⁹, Simonsson B¹⁰
¹Bristol-Myers Squibb, Princeton, NJ, USA, ²Winship Cancer Institute of Emory University, Atlanta, GA, USA, ³John Theurer Cancer Center, Hackensack, NJ, USA, ⁴Memorial Sloan-Kettering Cancer Center, New York, NY, USA, ⁵Centre Hospitalier Lyon-Sud, Pierre-Bénite, France, ⁶UCLA Medical Centre, Los Angeles, CA, USA, ⁷ICON Clinical Research, San Francisco, CA, USA, ⁸Bristol-Myers Squibb, Paris, France, ⁹Universität Heidelberg, Mannheim, Germany, ¹⁰Uppsala Universitet, Uppsala, Sweden

Presentation Documents

PCN63--strong-u-zyczynski-t-u-sup-1-sup-strong-khoury-j-sup-2-sup-goldberg-s-sup-3-sup-mauro-m-sup-4-sup-michallet-m-sup-5-sup-paquette-r-sup-6-sup-foreman-a-sup-7-sup-subar-m-sup-1-sup-turner-m-sup-7-sup-manley-daumont-m-sup-8-sup-hehlmann ...

OBJECTIVES: Understand time to and reasons for discontinuation or switching of imatinib in pts with CP-CML (≥12 months follow-up) in routine clinical practice. METHODS: SIMPLICITY (NCT01244750) is an ongoing study of pts receiving first-line imatinib prior to 2010 (retrospective) or first-line imatinib, dasatinib or nilotinib since 2010 (prospective) in the US and Europe. RESULTS: CONCLUSIONS: The proportion of pts with treatment interruptions was similar between cohorts; however, twice as many pts discontinued imatinib, and more switched to second-line TKI, in the prospective vs. retrospective cohort, perhaps due to treatment landscape changes. Intolerance was the primary reason for discontinuation, including switching. These findings suggest intolerance remains an issue and highlights the need for effective management of adverse events as well as second-generation treatment options.

Conference/Value in Health Info

2016-09, ISPOR Asia Pacific 2016, Singapore

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PCN63

Topic

Health Service Delivery & Process of Care

Topic Subcategory

Treatment Patterns and Guidelines

Disease

Oncology

Explore Related HEOR by Topic

Healthcare Delivery

Presentation